Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiteVax-adjuvanted influenza vaccine
- Development stage
- Unknown
- Lead developer
- LiteVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LiteVax-adjuvanted influenza vaccine is an investigational vaccine candidate developed by Litevax B.V. that incorporates a novel carbohydrate-based adjuvant. The adjuvant, LiteVax (LVX), consists of sucrose fatty acid sulfate esters (SFASE) and is designed to significantly enhance the immunogenicity of influenza antigens, such as those from H5N1 or seasonal strains. By stimulating both Th1 and Th2 immune pathways, the vaccine aims to provide robust protection and potentially allow for dose-sparing of the viral antigens. It is primarily being evaluated for its ability to improve vaccine efficacy in older adults and to provide protection against pandemic influenza strains.
- Other names
- LiteVax-adjuvanted H5N1 vaccineLVX-adjuvanted influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on LiteVax-adjuvanted influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LiteVax-adjuvanted influenza vaccine.